NewsBenzingaAprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On... Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On... Benzinga 2026.09.22 12:33 (GMT+0) Open on Benzinga Other news Elon Musk Admits He Has ‘No Idea’ How to Make Chips. Tesla Investors May Help Pay for Him to Learn. AI Sector Pressure, Earnings and Other Key Things to Watch this Week Disney agrees to hire the majority of Character.AI’s workforce Dividend Announcements: October 10-16, 2026 30 Dividend Buys You Might Hold Forever From October’s Russell 3000 Index TechCrunch Mobility: Rivian’s next act
